Cutaneous adverse events with antibody-drug conjugates: a FAERS-based pharmacovigilance study - Top-Institutions - MDSpire

Cutaneous adverse events with antibody-drug conjugates: a FAERS-based pharmacovigilance study

  • By

  • Huiwen Sun

  • Jinhan Chen

  • Qian Xu

  • Chen Chen

  • Jinsheng Yu

  • Qijin Shu

  • May 25, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Dermatology
    • Oncology

  • #2

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Dermatology
    • Oncology

  • #3

    European Organisation for Research and Treatment of Cancer
    European Organisation for Research and Treatment of Cancer

    Brussels, Belgium

    Key Differentiators

    • Oncology
    • Clinical Research

  • #4

    Ohio State University
    Ohio State University

    Columbus, OH

    Key Differentiators

    • Dermatology
    • Oncology

  • #5

    Institut Curie
    Institut Curie

    Paris, France

    Key Differentiators

    • Oncology
    • Clinical Research

Original Source(s)

Cutaneous adverse events with antibody-drug conjugates: a FAERS-based pharmacovigilance study

  • by Huiwen Sun, Jinhan Chen, Qian Xu, Chen Chen, Jinsheng Yu, Qijin Shu

  • May 25, 2026

Related Content

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series